

DEC. 13. 2002 3:06PM

GLAXO WELLCOME

NO. 6865 P. 1

#74C  
Dix  
12/16/02



GlaxoSmithKline

## FAX

To Examiner Priebe, Scott David, Group 1632  
.....  
Company USPTO  
.....  
Fax 703-872-9306  
.....  
From Marjorie J. Pfeiffer  
.....  
Tel 1-919-483-9038; Facsimile: 1-919-483-7988  
.....  
E-mail Mjp14849@gsk.com  
.....  
Date December 13, 2002 Pages including cover 9  
.....  
Subject Request for Continued Examination (RCE) and  
.....  
Extension of Time  
.....

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100

FAX RECEIVED

DEC 16 2002

GROUP 1600

OFF

Re: Request for Continued Examination (RCE) and Extension of Time  
Application of BRADDOCK et al.  
U.S. Serial No.: 09/743,516; Filed: January 31, 2001  
Examiner: Priebe, Scott David; Group Art: 1632  
Title: *Pharmaceutical Uses of NAB1 and NAB2*  
Attorney Docket No. PU3506USw

### Attached:

1. Request for Continued Examination (RCE) including Certificate of Transmission (37 CFR 1.8(a))  
(in duplicate)
2. Petition for Extension of Time (in duplicate)
3. Amendment (4 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Received from <919 483 7988> at 12/13/02 1:30:24 PM [Eastern Standard Time]

#13  
12/16/02

PTO/SB/30 (10/2001)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	09/143,516
Filing Date	January 31, 2001
First Named Inventor	Martin BRADDOCK
Art Unit	1632
Examiner Name	Priebe, Scott David
Attorney Docket Number	PG3506USw

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

## 1. Submission required under 37 CFR §1.114

### a. ☐ Previously submitted

i. ☐ Consider the amendment(s)/reply under 37 CFR §1.116 previously filed on \_\_\_\_\_

(Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_

iii. ☐ Other \_\_\_\_\_

### b. ☒ Enclosed

i. ☒ Amendment/Reply

iii. ☐ Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/Declaration(s)

iv. ☒ Other Petition and Fee for Extension of Time

## 2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR §1.103(c) for a period of \_\_\_\_\_ months (Period of suspension shall not exceed 3 months; Fee under 37 CFR §1.17(i) required)

b. ☐ Other \_\_\_\_\_

## 3. Fees

The RCE fee under 37 CFR §1.17(e) is required by 37 CFR §1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 07-1392

i. ☒ RCE fee required under 37 CFR §1.17(e)

ii. ☒ Extension of time fee (37 CFR §§1.136 and 1.17)


iii. ☐ Other \_\_\_\_\_

b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)


**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print / Type)	Michael M. Conger	Registration No. (Attorney / Agent)	43,562
Signature		Date	December 13, 2002

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, by first class mail with return receipt requested. 0974 516

Name (Print / Type)	Marjorie J. Pfeiffer	Date	December 13, 2002 40.00 CH
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.